コンテンツへスキップ
Merck
  • Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.

Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.

Antimicrobial agents and chemotherapy (2008-06-04)
Amélie Carrër, Laurent Poirel, Haluk Eraksoy, A Atahan Cagatay, Selim Badur, Patrice Nordmann
要旨

The first outbreak of carbapenem-resistant Klebsiella pneumoniae isolates producing the plasmid-encoded carbapenem-hydrolyzing oxacillinase OXA-48 is reported. The 39 isolates belonged to two different clones and were collected at the University Hospital of Istanbul, Turkey, from May 2006 to February 2007, and they coproduced various beta-lactamases (SHV-12, OXA-9, and TEM-1 for clone A and CTX-M-15, TEM-1, and OXA-1 for clone B).

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
トリメトプリム, ≥98.5%
Sigma-Aldrich
アモキシシリン, 95.0-102.0% anhydrous basis
Sigma-Aldrich
テトラサイクリン, 98.0-102.0% (HPLC)
Sigma-Aldrich
トリメトプリム, ≥99.0% (HPLC)
Sigma-Aldrich
オフロキサシン, fluoroquinolone antibiotic
Sigma-Aldrich
シプロフロキサシン, ≥98% (HPLC)
Sigma-Aldrich
ナリジクス酸, ≥98%
Supelco
ノルフロキサシン, analytical standard, ≥98% (TLC)
Supelco
トリメトプリム, VETRANAL®, analytical standard
Supelco
シプロフロキサシン, VETRANAL®, analytical standard
Supelco
オフロキサシン, VETRANAL®, analytical standard
Supelco
ノルフロキサシン, VETRANAL®, analytical standard